Can-Fite Advances Piclidenoson into Rare Disease Trial for Lowe Syndrome
Event summary
- Can-Fite submits Phase 2 protocol for Piclidenoson in Lowe Syndrome, a rare genetic disorder with no approved therapies.
- Study will enroll 5 adult patients at Bambino Gesù Children's Hospital in Rome, led by Prof. Francesco Emma.
- Piclidenoson's selection based on preclinical data showing restoration of OCRL-dependent cellular function.
- Phase 2 trial is open-label, single-center, with primary endpoint measuring renal uptake improvement.
The big picture
Can-Fite's move into Lowe Syndrome represents a strategic pivot toward rare diseases, leveraging Piclidenoson's anti-inflammatory mechanism. The collaboration with Fondazione Telethon and Bambino Gesù Children's Hospital underscores the high unmet need in this space. Success here could open new regulatory pathways for orphan drug designations, but the small patient population and trial size pose execution risks.
What we're watching
- Regulatory Pathway
- Whether the Phase 2 data will support discussions with regulatory authorities for potential registration.
- Clinical Execution
- The pace at which Can-Fite can enroll and complete the small pilot study in Lowe Syndrome patients.
- Strategic Expansion
- How this rare disease program will impact Piclidenoson's broader development, particularly alongside its Phase 3 psoriasis trial.
Related topics